COVID-19 rapid test VYRA™CoV2

for antigensSARS-COV-2influenza A

All products are based on MedMira’s patented RVF Technology® and allow a fast, reliable and easy-to-use solution for any settings, specifically for Point-of-Care use. MedMira’s products do not require any other instruments or special settings. Designed to be used from laboratories to home-users All MedMira’s Products have the following unique features: Inexpensive, portable device DOES NOT REQUIRE Specialized equipment, additional reagents and skillful workers Sophisticated sample preparation ALLOWS Widespread testing (including asymptomatic patients) USEFUL IN Follow-up screening Vaccine development VYRA™CoV2 detects antigens specific for the nucleocapsid region of SARS-CoV-2, the causative agent of COVID-19, and can determine an active infection in less than 3 minutes. It comes as a fast solution to screen for individuals who are suspected of COVID-19 infection. Point-of-Use : Intended for the qualitative detection of SARS-CoV-2 antigens in nasal swab specimens. VYRA™COVID-19 is intended for use by healthcare professionals as an aid in identifying individuals with an acute SARS-CoV-2 infection. VYRA™CoV2Flu is a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2 and Influenza A (Flu A) and Influenza B (Flu B). VYRACoV2Flu is the right tool to screen and differentiate between the viruses causing COVID-19 and Flu A / Flu B. Point-of-Use : A manually performed, visually interpreted Rapid Vertical Flow® (RVF®) immunoassay design to detect SARS-CoV-2, Influenza A and/or Influenza B viruses, the causative agents of COVID-19 and seasonal flu, respectively, in the human throat and/or nasal swab specimens.